(Reuters) – Novo Holdings has completed its $16.5 billion takeover of Catalent (NYSE:), the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk (NYSE:), which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy.
